Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
TLDR
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.Abstract:
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space. Magnetic resonance imaging is integrated with dinical and other paraclinical diagnostic methods. The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including "monosymptomatic" disease suggestive of MS, disease with a typical relapsing-remitting course, and disease with insidious progression, without clear attacks and remissions. Previously used terms such as "clinically definite" and "probable MS" are no longer recommended. The outcome of a diagnostic evaluation is either MS, "possible MS" (for those at risk for MS, but for whom diagnostic evaluation is equivocal), or "not MS."read more
Citations
More filters
Journal ArticleDOI
A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility.
Stephen Sawcer,Mel Maranian,Efrosini Setakis,Val Curwen,Eva Åkesson,Anke Hensiek,Francesca Coraddu,Richard Roxburgh,David Sawcer,Julia Gray,J. Deans,Peter N. Goodfellow,Neil Walker,David Clayton,Alastair Compston +14 more
TL;DR: The results thus provide further supporting evidence for the candidature of 6p, 17q, 19q and 1p as regions encoding susceptibililty genes for multiple sclerosis.
Journal ArticleDOI
Effects of Bacille Calmette-GuÉrin after the first demyelinating event in the CNS
Giovanni Ristori,Silvia Romano,Stefania Cannoni,Andrea Visconti,Emanuele Tinelli,Laura Mendozzi,Pietro Cecconi,Roberta Lanzillo,Mario Quarantelli,Carla Buttinelli,Claudio Gasperini,M. Frontoni,Giulia Coarelli,Domenico Caputo,Vincenzo Bresciamorra,Nicola Vanacore,Carlo Pozzilli,Marco Salvetti +17 more
TL;DR: BCG, as compared to placebo, was associated with significantly reduced development of gadolinium-enhancing lesions in people with CIS for a 6-month period before starting immunomodulating therapy (Class I evidence).
Journal ArticleDOI
Treatment optimization in multiple sclerosis.
Mark S. Freedman,David G. Patry,Francois Grand'Maison,Mary Lou Myles,Donald W. Paty,Daniel Selchen +5 more
TL;DR: Using a recently published model as a framework, The Canadian Multiple Sclerosis Working Group developed practical recommendations on how neurologists can assess the status of patients on DMTs and decide when it may be necessary to modify treatment in order to optimize outcomes.
Journal ArticleDOI
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
Richard A. Nash,George J. Hutton,Michael K. Racke,Uday R. Popat,Steven M. Devine,Kaitlyn C. Steinmiller,Linda M. Griffith,Paolo A. Muraro,Harry Openshaw,Peter H. Sayre,Olaf Stüve,Douglas L. Arnold,Mark H. Wener,George E. Georges,Annette Wundes,George H. Kraft,James Bowen +16 more
TL;DR: This study provides Class IV evidence that participants with RRMS experienced sustained remissions with toxicities as expected from HDIT/HCT without maintenance therapy, and was effective for inducing long-term sustained remission of active RRMS at 5 years.
Journal ArticleDOI
Cognitive and motor functioning in patients with multiple sclerosis: neuropsychological predictors of walking speed and falls.
Vanessa L. D'Orio,Vanessa L. D'Orio,Frederick W. Foley,Frederick W. Foley,Francine Armentano,Mary Ann Picone,Sonya Kim,Sonya Kim,Roee Holtzer,Roee Holtzer +9 more
TL;DR: It is suggested that risk assessment for gait decline and falls should include cognitive assessment in patients with MS, as specific cognitive functions are meaningfully related to mobility limitations in Patients with MS.
References
More filters
Journal ArticleDOI
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Charles M. Poser,Donald W. Paty,Labe C. Scheinberg,W I McDonald,F A Davis,George C. Ebers,Kenneth P. Johnson,William A. Sibley,Donald H. Silberberg,Wallace W. Tourtellotte +9 more
TL;DR: Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Journal ArticleDOI
The clinical course of neuromyelitis optica (Devic's syndrome)
TL;DR: Clinical, laboratory, and imaging features generally distinguish neuromyelitis optica from MS, and patients with relapsing optic neuritis and myelitis may have neuromyeliitis opticas rather than MS.
Journal ArticleDOI
Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.
George A. Schumacher,Gilbert Beebe,Robert F. Kibler,Leonard T. Kurland,John F. Kurtzke,Fletcher McDowell,Benedict Nagler,William A. Sibley,Wallace W. Tourtellotte,Thomas L. Willmon +9 more
TL;DR: Since its etiology and pathogenesis have eluded detection, it is not surprising that therapeutic attempts have been empiric and often unscientific.
Journal ArticleDOI
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Frederik Barkhof,Massimo Filippi,David Miller,Philip Scheltens,Adriana Campi,Chris H. Polman,Giancarlo Comi,Herman J. Adèr,N. A. Losseff,Jacob Valk +9 more
TL;DR: It is concluded that a four-parameter dichotomized MRI model including gadolinium-enhancement, juxtacortical, infratentorial and periventricular lesions best predicts conversion to clinically definite multiple sclerosis.
Journal ArticleDOI
MRI in the diagnosis of MS A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT
Donald W. Paty,Joel Oger,Lorne F. Kastrukoff,S. A. Hashimoto,John P. Hooge,Andrew Eisen,K. A. Eisen,S. J. Purves,M. D. Low,V. Brandejs,W. D. Robertson,David Kb Li +11 more
TL;DR: MRI was the best method for demonstrating dissemination in space and laboratory-supported definite MS (LSDMS) could be diagnosed in 85 patients of the total 200, and MRI predicted that diagnosis in 18/19 (95%).
Related Papers (5)
Rating neurologic impairment in multiple sclerosis An expanded disability status scale (EDSS)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more